throughout the monitoring period. The other 40 cytokines did not show significant trend between responders and non responders. Thus, sCD25 and TNFb can be potentially used as biomarkers to predict response of cGvHD to ECP. Studies with larger number of patients on ECP will be required to confirm these findings.
The cGVHD Symptom Bother Scale, known as the Lee cGVHD scale, is a patient reported questionnaire developed and validated in English to measure symptoms and functional losses in patients (pts.) with cGVHD. The Lee cGVHD scale includes 30 questions with 7 subscales containing 2 to 7 items representing domains of skin, mouth, respiratory system, gastrointestinal system, energy and psychological status. The Lee cGVHD scale was translated into Portuguese and validated according to the American Association of Orthopedic Surgeons Outcome Committee guideline. 47 adult pts with cGVHD diagnosed according to the 2005 NIH consensus criteria were studied by the Brazil-Seattle cGVHD Consortium between 2011 to 2012 at 5 centers. Median age was 48 years (23-69) and 29 (61.7%) were male. All pts. completed the Brazilian version of the Lee cGVHD questionnaire, the Medical Outcomes Study Short Form 36 (SF-36) and the Functional Assessment of Chronic Illness Therapy with Bone Marrow Transplant subscale (FACT-BMT). Overall cGVHD severity was also assessed by pt. (0-3 scale) and by physician (0-10 scale). Reliability was assessed using Cronbach's alpha and intraclass correlation coefficients. Spearman's correlation coefficient was used to measure construct validity. Results showed the reliability of the Lee cGVHD scale was satisfactory (Cronbach's alpha 0.62-0.83). Correlation coefficients were moderate between similar domains of the Lee cGVHD scale, SF-36, FACT-BMT and overall cGVHD severity as rated by the physician but, correlation was low between Lee cGVHD scale and overall cGVHD severity assessed by patient (Table) Background: Allogeneic hematopoietic stem cell transplantation is a curative treatment for a number of hematological malignancies. Graft-versus-host disease (GVHD) remains a leading cause of morbidity and mortality. Rabbit anti-thymocyte globulin (ATG) is used to reduce the incidence of GVHD. However, dosing regimens and schedules vary. Methods: We reviewed the medical records of 88 patients at our institution who received ATG at either 4.5 or 6.0mg/kg, in combination with tacrolimus and mycophenolate, prior to allogeneic stem cell transplantation between 2009 and 2011. ATG was administered over 3 days, finishing on day 0. We retrospectively evaluated the prophylactic effect of each ATG dosing regimen by measuring the incidence of severe (grade III-IV) acute GVHD and acute GVHD-associated mortality. We also measured relapse rate, overall survival (OS) and progression-free survival (PFS) for both groups. Results: A total of 52 patients who received ATG at 4.5mg/kg (ATG1) were compared with 36 patients who received ATG at 6.0mg/kg (ATG2). The degree of HLA-mismatching was greater in ATG2 (39.1% mismatched unrelated donors) as compared to ATG1 (10% mismatched unrelated donors) (P¼0.019) among 53 recipients from unrelated donors. Median follow up for ATG1 was 362 days, as compared to 512 days for ATG2. The cumulative incidence of grade III-IV acute GVHD at day 100 was 13.9% and 6.5% in the ATG1 and ATG2 groups, respectively (P¼0.256). Specifically, 6 patients in ATG1 developed grade IV GHVD, as compared to 0 patients in ATG2. Acute GVHD-associated mortality was 7.7% and 0% in ATG1 and ATG2, respectively (P¼0.141). All GVHD-associated deaths occurred in patients with grade IV GVHD. The relapse rates were comparable between ATG1 and ATG2 for both Other Evaluations Lee chronic GVHD Scale (0-100) Background: Previous studies have shown that patients receiving AHSCT are likely to have sub-optimal Vit D levels. Vit D has also been shown to have significant immunomodulatory effects, including polarization of T cell population towards Th2 expression and decreasing allogeneic T-cell proliferation while increasing T-reg cell function. Alloreactive T cells upregulate the Vit D receptor and repletion of Vit D in vitro significantly reduces this response. Thus it is hypothesized that patients with VIT D deficiency at onset of AHSCT would have greater incidence and severity of GVHD and that early replacement may lessen the risk of GVHD. In this study we examine this relationship. Methods: A retrospective evaluation of 290 adult AHSCT at the University of Michigan between January 2007-December 2010. All patients had Serum 25-hydorxyvitamin D (25OHD) levels at admission for AHSCT. Deficient levels were defined to be below 29 ng/ml and normal levels as 30 ng/ml or higher. The incidence and grade of GVHD were defined as maximum overall grade and acute GVHD was defined as starting within the first 100 days. The primary standard GVHD prophylaxis regimens were Tacrolimus/MTX for full intensity and Tacrolimus /MMF for reduced intensity transplants. Results: Of all AHSCT 77% had Vit D deficiency at onset of transplant with no difference between related donors (RD) and unrelated donors (UD). Vit D supplementation was started within the first week of transplant and occurred in 83% who were Vit D deficient at baseline and 36% of those having normal levels at baseline. In patients with baseline Vit D deficiency there did not appear to be an impact of Vit D supplementation on the incidence of Grade 2-4 GVHD (44% vs 46%) or Grade 3-4 GVHD (17% vs 19%). However in patients who had baseline Vit D levels of 30 ng/ml or above there was a significant decrease in the incidence of Grade 3-4 GVHD in the group who received Vit D supplementation versus those who did not (9% vs 27%, X 2 ¼2.99,P ¼ .042) and a trend towards a decrease in Grade 2-4 GVHD (35% vs 54%, X 2 ¼2.11,P ¼ .073). This is despite having more Unrelated Donor transplants in the Vit D supplemented group (65% vs 46%).
Conclusion: AHSCT patients have high rates of Vit D deficiency. Ironically this study suggests that Vit D supplementation starting during transplant may significantly decrease the incidence of Grade 3-4 GVHD in patients who have baseline levels >30 ng/ml but not those severely deficient at baseline. This could imply that higher amounts of Vit D supplementation may be required to adequately effect T cell response. Future trials should evaluate the role of increasing Vit D supplementation and determine if an optimal Vit D level is required to decrease the incidence and severity of acute GVHD.
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Contribution of the PDe1ePDeL Pathway to Chronic GrafteVersuseHost Disease Hideaki Fujiwara, Koichiro Kobayashi, Hisakazu Nishimori, Masaaki Nishinohara, Sachiyo Okamoto, Ken-ichi Matsuoka, Eisei Kondo, Nobuharu Fujii, Katsuji Shinagawa, Mitsune Tanimoto, Yoshinobu Maeda. Department of Hematology and Oncology, Okayama University Graduate School, Okayama, Japan
Chronic graft-versus-host disease (cGVHD) remains a major cause of late phase mortality and morbidity after allogeneic hematopoietic stem cell transplantation. We investigated the roles of the PD-1 pathway in cGVHD using a well-defined mouse model (B10.D2 into BALB/c). First, we confirmed that CD4 and CD8 cells from the spleen and peripheral lymph nodes (PLN) of allogeneic recipients expressed significantly more PD-1 compared to those of syngeneic recipients on days 14, 21, 28, and 56 after transplantation (p < 0.05). Upon transferring PD-1 KO donor T cells of the B10.D2 background into allogeneic bone marrow transplantation (BMT) models, there was severe weight loss and 100% of the recipients died by day 23. To avoid early death and to examine the roles of the PD-1 pathway in cGVHD, we next administered six antibody doses to recipients of wild-type (WT) donors from day 14 of BMT, just prior to the development of cGVHD. Mice treated with anti-PD-1 showed 70% mortality by day 35 in contrast to only 10% mortality in those administered anti-B7H1 Ab or anti-B7DC Ab. All groups treated with anti-PD-1 Ab, anti-B7H1 Ab, or anti-B7DC Ab had significantly higher cGVHD scores than controls (anti-PD-1 Ab: 2.51AE0.31, anti-B7H1 Ab: 2.31AE0.15, anti-B7DC Ab: 2.01AE0.42, vs. control: 1.18AE0.27, P < .05). To further examine the roles of the PD-1 pathway in cGVHD, we next used B7H1 KO mice as recipients. Allogeneic B7H1 KO BMT recipients showed significantly more severe skin cGVHD than WT controls (p < 0.05). Histopathological examination of the skin showed significantly increased cGVHD damage in recipients of B7H1 KO donors (5.86 AE 0.85 vs. 8.38 AE 0.38, P < 0.05). Since B7H1 expression of hematopoietic cells is critical for donor Treg cell expansion, we then harvested cells from PLNs 14 and 28 days after BMT and analyzed cytokine expression levels. Recipients of B7H1 KO showed fewer Foxp3+ regulatory T cells in the early phase (day 14), whereas there was no difference in the frequency of Foxp3+ regulatory T cells in the late phase (day 28). We previously reported that Th1 and Th17 cells contribute to the pathogenesis of cGVHD using this mouse model. On day 28, IL-17+ IFNg+ T cells were detected significantly more frequently in recipients of B7H1 KO donors than those of WT recipients (p < 0.05). These results suggested that B7H1 expression in the recipient regulates the frequency of IL-17+ IFNg+ T cells and Foxp3+ regulatory T cells. Finally, we established chimeras that expressed B7H1 in hematopoietic cells, but not in parenchymal tissue by transferring WT BM cells into B7H1KO recipients. Chimeric
